XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing to a pivotal study stage; the pilot study evaluated the use of the Rotigotine transdermal patch in the treatment for Parkinson’s disease. In addition, the update noted that XPhyto had purchased land in Germany for the construction of its commercial drug manufacturing facility in Germany. The company’s drug formulation and development projects are conducted primarily by XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH, a company focused on the development of generic and hybrid-generic drug formulations for neurological conditions through its transdermal and oral dissolvable drug delivery platforms. “Vektor continues to build shareholder value by advancing its product development pipeline,” said XPhyto CEO & Director Hugh Rogers in the press release. “Its lead program is now progressing to a pivotal human study in Europe, which is the final major milestone on the path to commercial regulatory approval. The addition of in-house, scalable commercial drug manufacturing capability is expected to add further value and optionality to XPhyto’s drug formulation and manufacturing businesses.”
To view the full press release, visit https://ibn.fm/EOlFK
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
